Chimeric Cyanovirin-MPER Recombinantly Engineered Proteins Cause Cell-Free Virolysis of HIV-1

被引:20
作者
Contarino, Mark [1 ]
Bastian, Arangassery R. [1 ,2 ]
Sundaram, Ramalingam Venkat Kalyana [1 ,2 ]
McFadden, Karyn [3 ]
Duffy, Caitlin [1 ]
Gangupomu, Vamshi [4 ]
Baker, Michelle [4 ]
Abrams, Cameron [1 ,4 ]
Chaiken, Irwin [1 ]
机构
[1] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19104 USA
[2] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA
[3] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA
[4] Drexel Univ, Dept Chem & Biol Engn, Philadelphia, PA 19104 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; MICROBICIDE DEVELOPMENT; INACTIVATING PROTEIN; GP120; ENTRY; FUSION; GP41; INHIBITION; MEMBRANE; RECEPTOR;
D O I
10.1128/AAC.00309-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus (HIV) is the primary etiologic agent responsible for the AIDS pandemic. In this work, we used a chimeric recombinant protein strategy to test the possibility of irreversibly destroying the HIV-1 virion using an agent that simultaneously binds the Env protein and viral membrane. We constructed a fusion of the lectin cyanovirin-N (CVN) and the gp41 membrane-proximal external region (MPER) peptide with a variable-length (Gly(4)Ser)(x) linker (where x is 4 or 8) between the C terminus of the former and N terminus of the latter. The His-tagged recombinant proteins, expressed in BL21(DE3)pLysS cells and purified by immobilized metal affinity chromatography followed by gel filtration, were found to display a nanomolar efficacy in blocking BaL-pseudotyped HIV-1 infection of HOS.T4.R5 cells. This antiviral activity was HIV-1 specific, since it did not inhibit cell infection by vesicular stomatitis virus (VSV) or amphotropic-murine leukemia virus. Importantly, the chimeric proteins were found to release intraviral p24 protein from both BaL-pseudotyped HIV-1 and fully infectious BaL HIV-1 in a dose-dependent manner in the absence of host cells. The addition of either MPER or CVN was found to outcompete this virolytic effect, indicating that both components of the chimera are required for virolysis. The finding that engaging the Env protein spike and membrane using a chimeric ligand can destabilize the virus and lead to inactivation opens up a means to investigate virus particle metastability and to evaluate this approach for inactivation at the earliest stages of exposure to virus and before host cell encounter.
引用
收藏
页码:4743 / 4750
页数:8
相关论文
共 28 条
[1]   Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein - Implications for therapeutic and vaccine strategies [J].
Arthos, J ;
Cicala, C ;
Steenbeke, TD ;
Chun, TW ;
Cruz, CD ;
Hanback, DB ;
Khazanie, P ;
Nam, D ;
Schuck, P ;
Selig, SM ;
Van Ryk, D ;
Chaikin, MA ;
Fauci, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) :11456-11464
[2]   Cell-Free HIV-1 Virucidal Action by Modified Peptide Triazole Inhibitors of Env gp120 [J].
Bastian, Arangassery R. ;
Kantharaju ;
McFadden, Karyn ;
Duffy, Caitlin ;
Rajagopal, Srivats ;
Contarino, Mark R. ;
Papazoglou, Elisabeth ;
Chaiken, Irwin .
CHEMMEDCHEM, 2011, 6 (08) :1335-1339
[3]   Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120 [J].
Bennett, Adam ;
Liu, Jun ;
Van Ryk, Donald ;
Bliss, Donald ;
Arthos, James ;
Henderson, Robert M. ;
Subramaniam, Sriram .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (38) :27754-27759
[4]   Solution structure of cyanovirin-N, a potent HIV-inactivating protein [J].
Bewley, CA ;
Gustafson, KR ;
Boyd, MR ;
Covell, DG ;
Bax, A ;
Clore, GM ;
Gronenborn, AM .
NATURE STRUCTURAL BIOLOGY, 1998, 5 (07) :571-578
[5]   Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development [J].
Boyd, MR ;
Gustafson, KR ;
McMahon, JB ;
Shoemaker, RH ;
OKeefe, BR ;
Mori, T ;
Gulakowski, RJ ;
Wu, L ;
Rivera, MI ;
Laurencot, CM ;
Currens, MJ ;
Cardellina, JH ;
Buckheit, RW ;
Nara, PL ;
Pannell, LK ;
Sowder, RC ;
Henderson, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1521-1530
[6]   Structural organization of authentic, mature HIV-1 virions and cores [J].
Briggs, JAG ;
Wilk, T ;
Welker, R ;
Kräusslich, HG ;
Fuller, SD .
EMBO JOURNAL, 2003, 22 (07) :1707-1715
[7]   HIV entry and its inhibition [J].
Chan, DC ;
Kim, PS .
CELL, 1998, 93 (05) :681-684
[8]   Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor [J].
Cocklin, Simon ;
Gopi, Hosahudya ;
Querido, Bianca ;
Nimmagadda, Manideepthi ;
Kuriakose, Syna ;
Cicala, Claudia ;
Ajith, Sandya ;
Baxter, Sabine ;
Arthos, James ;
Martin-Garcia, Julio ;
Chaiken, Irwin A. .
JOURNAL OF VIROLOGY, 2007, 81 (07) :3645-3648
[9]   Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development [J].
Colleluori, DM ;
Tien, D ;
Kang, FR ;
Pagliei, T ;
Kuss, R ;
McCormick, T ;
Watson, K ;
McFadden, K ;
Chaiken, I ;
Buckheit, RW ;
Romano, JW .
PROTEIN EXPRESSION AND PURIFICATION, 2005, 39 (02) :229-236
[10]   VPR IS REQUIRED FOR EFFICIENT REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN MONONUCLEAR PHAGOCYTES [J].
CONNOR, RI ;
CHEN, BK ;
CHOE, S ;
LANDAU, NR .
VIROLOGY, 1995, 206 (02) :935-944